Absci Stock (NASDAQ:ABSI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.72

52W Range

$1.35 - $6.72

50D Avg

$3.90

200D Avg

$4.34

Market Cap

$307.81M

Avg Vol (3M)

$990.55K

Beta

2.19

Div Yield

-

ABSI Company Profile


Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

155

IPO Date

Jul 22, 2021

Website

ABSI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 21
Collaborative Revenue$136.00K
Technology Development Revenue$592.00K

Fiscal year ends in Dec 23 | Currency in USD

ABSI Financial Summary


Dec 23Dec 22Dec 21
Revenue$5.72M$5.75M$4.78M
Operating Income$-93.68M$-106.75M$-75.24M
Net Income$-110.57M$-104.90M$-100.96M
EBITDA$-79.68M$-91.36M$-99.77M
Basic EPS$-1.20$-1.15$-1.09
Diluted EPS$-1.20$-1.15$-1.09

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 10:01 AM
Q2 24Aug 16, 24 | 11:50 PM
Q1 24May 14, 24 | 1:30 PM

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
XFORX4 Pharmaceuticals, Inc.
CFRXContraFect Corporation
DTILPrecision BioSciences, Inc.
VECTVectivBio Holding AG
DAWNDay One Biopharmaceuticals, Inc.
RLAYRelay Therapeutics, Inc.
RXRXRecursion Pharmaceuticals, Inc.
GRPHLENZ Therapeutics, Inc.
AVROAVROBIO, Inc.
CRBUCaribou Biosciences, Inc.
INZYInozyme Pharma, Inc.
AFMDAffimed N.V.
ABOSAcumen Pharmaceuticals, Inc.
HEPAHepion Pharmaceuticals, Inc.
EXAIExscientia plc
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.